Navigation Links
Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
Date:1/29/2008

IRVINE, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, today announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) for a revised design to the U.S. pivotal clinical trial of the Edwards SAPIEN transcatheter aortic heart valve technology. The FDA approved the addition of the Ascendra transapical delivery system to the trial, and also granted permission to Edwards to increase its trial sample size from 600 patients to 1,040 patients.

The PARTNER (Placement of AoRTic traNscathetER valves) trial, initiated in the second quarter of 2007, is evaluating the Edwards SAPIEN valve in patients who are considered high risk or inoperable for conventional open-heart valve surgery.

"The addition of the Ascendra transapical delivery system to the PARTNER trial will enable Edwards to address a larger population of patients who may have few or no options for treatment of their heart valve disease," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. "Incorporating Ascendra along with increasing the number of patients in the trial also will better ensure that the trial endpoints are successfully met."

With these trial revisions, patients with symptomatic, calcific aortic stenosis -- a narrowing of the aortic valve that reduces the outward flow of oxygenated blood -- will be evaluated for inclusion in one of two separate treatment arms, surgical or medical management. "The addition of the transapical approach to the PARTNER trial is an important milestone for cardiac surgeons and their patients. The transapical approach greatly expands the options for patients who need aortic valve replacement, but face excessive risk with alternative approaches," said Craig Smith, M.D., Chief of the Division of Cardiothoracic Surgery at New York-Presbyterian Hospital/Columbia University Medical Center and the co-principal investigator for the U.S. PARTNER trial.

The surgical arm of the trial evaluates the Edwards SAPIEN valve and the two transcatheter delivery systems -- Ascendra for transapical access, and RetroFlex for transfemoral access -- as compared to surgical, open-heart valve replacement. The medical management arm of the trial evaluates the Edwards SAPIEN valve with the RetroFlex transfemoral delivery system as compared to appropriate medical therapy.

Edwards has significant experience with transcatheter valve procedures based on more than 600 implants of the transcatheter heart valve through a series of extensive clinical trials and feasibility studies in Europe, the U.S. and Canada. The Edwards SAPIEN valve with the Ascendra transapical and RetroFlex transfemoral delivery systems is commercially available in Europe.

About Edwards Lifesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to the company's ability to successfully complete the PARTNER clinical trial, timely regulatory approval of the Edwards SAPIEN transcatheter aortic heart valve and the market for transcatheter technologies. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2006.

Ascendra, Edwards, Edwards SAPIEN and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
2. Edwards Lifesciences Forecasts Strong Growth in 2008
3. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
9. A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens
10. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
11. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):